Back to top Open menu arrow
Download Reprints
Sections
METHODS RESULTS DISCUSSION Clinical Points
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

Systematic Review Early Career Psychiatrists May 10, 2023

Control Conditions in Randomized Trials of Psychedelics: An ACTTION Systematic Review

Sandeep M. Nayak, MD; Melissa K. Bradley, BA; Bethea A. Kleykamp, PhD; Eric C. Strain, MD; Robert H. Dworkin, PhD; Matthew W. Johnson, PhD

J Clin Psychiatry 2023;84(3):22r14518

ABSTRACT

Objective: To systematically review control conditions of all available randomized psychedelic trials.

Data Sources: We searched PubMed, PsycINFO, and EMBASE for randomized trials of psychedelics in humans from 1940 through May 2020 with no language restrictions. PRISMA guidelines were followed. (PROSPERO registration number: PROSPERO-CRD42020205341.)

Study Selection: All randomized trials of psychedelics in humans from 1940 through May 2020 were included.

Data Extraction: Two independent reviewers performed extraction. Extracted data included study design, demographics, blinding type, whether and how blind integrity was assessed, psychedelic used and dose, drug control condition and dose, type of non-drug control condition, number of dosing sessions, and recruitment source. Outcome data were not collected.

Results: In total, 126 articles were included, encompassing 86 unique studies. Of studies with a drug control condition (80), 49 (61.2%) used an inert placebo control, 16 (20.0%) used active comparators, 12 (15.0%) used both, and 3 (3.8%) used only different active psychedelic doses as a control. Only 3 of 21 therapeutic trials compared the use of psychological support to a minimally supportive condition. The majority (81/86; 94%) of studies were blinded, though only 14 (17.3%) included blind assessment; only 8 of these 14 studies assessed participants’ blinding. Blinding success, assessed in highly varied ways, was generally poor.

Conclusions: Randomized psychedelic trials underutilize elements that would improve quality or provide important information: blind assessment, active drug controls, and testing psychological support against minimal-support conditions. Several queried categories, including blind integrity assessment and details of non-drug control conditions, were insufficiently reported by many reviewed studies. Recommendations are provided to improve trial methods.

 

 

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

  1. Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78(5):481–489. PubMed CrossRef
  2. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384(15):1402–1411. PubMed CrossRef
  3. Johnson MW, Garcia-Romeu A, Cosimano MP, et al. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983–992. PubMed CrossRef
  4. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181–1197. PubMed CrossRef
  5. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165–1180. PubMed CrossRef
  6. Bogenschutz MP, Forcehimes AA, Pommy JA, et al. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29(3):289–299. PubMed CrossRef
  7. Schindler EAD, Sewell RA, Gottschalk CH, et al. Exploratory controlled study of the migraine-suppressing effects of psilocybin. Neurotherapeutics. 2021;18(1):534–543. PubMed CrossRef
  8. Aday JS, Heifets BD, Pratscher SD, et al. Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology (Berl). 2022;239(6):1989–2010. PubMed CrossRef
  9. Muthukumaraswamy SD, Forsyth A, Lumley T. Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol. 2021;14(ja):1133–1152. PubMed CrossRef
  10. Yaden DB, Griffiths RR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2020;4(2):568–572. PubMed CrossRef
  11. Nayak S, Johnson MW. Psychedelics and psychotherapy. Pharmacopsychiatry. 2021;54(4):167–175. PubMed
  12. Gukasyan N, Nayak SM. Psychedelics, placebo effects, and set and setting: insights from common factors theory of psychotherapy. Transcult Psychiatry. 2021;59(5):652-664. PubMed
  13. Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. PubMed CrossRef
  14. Tomsovic M, Edwards RV. Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: a controlled evaluation. Q J Stud Alcohol. 1970;31(4):932–949. PubMed CrossRef
  15. Savage C, Cabe OLM, Kurland AA, et al.. LSD-Assisted Psychotherapy in the Treatment of Severe Chronic Neurosis. Farmingdale, NY: Baywood Pub Co; 1973.
  16. Ludwig A, Levine J, Stark L, et al. A clinical study of LSD treatment in alcoholism. Am J Psychiatry. 1969;126(1):59–69. PubMed CrossRef
  17. Bowen WT, Soskin RA, Chotlos JW. Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: a follow-up study. J Nerv Ment Dis. 1970;150(2):111–118. PubMed CrossRef
  18. Johnson FG. LSD in the treatment of alcoholism. Am J Psychiatry. 1969;126(4):481–487. PubMed CrossRef
  19. Rhead J, Soskin R, Turek I. Psychedelic drug (DPT)-assisted psychotherapy with alcoholics: a controlled study. J Psychoactive Drugs. 1977;9(4):287–300. CrossRef
  20. Kurland A, Savage C, Pahnke WN, et al. LSD in the treatment of alcoholics. Pharmacopsychiatry. 1971;4(02):83–94. CrossRef
  21. Soskin RA. The use of LSD in time-limited psychotherapy. J Nerv Ment Dis. 1973;157(6):410–419. PubMed CrossRef
  22. Haertzen CA. On the addiction research center inventory scores of former addicts receiving LSD and untreated schizophrenics. Psychol Rep. 1964;14(2):483–488. CrossRef
  23. Isbell H, Logan CR. Studies on the diethylamide of lysergic acid (LSD-25), II: effects of chlorpromazine, azacyclonol, and reserpine on the intensity of the LSD-reaction. AMA Arch Neurol Psychiatry. 1957;77(4):350–358. PubMed CrossRef
  24. Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9(17):3897–3902. PubMed CrossRef
  25. Hollister LE, Degan RO, Schultz SD. An experimental approach to facilitation of psychotherapy by psychotomimetic drugs. J Ment Sci. 1962;108(452):99–100. PubMed CrossRef
  26. Holze F, Vizeli P, Müller F, et al. Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology. 2020;45(3):462–471. PubMed CrossRef
  27. Holze F, Duthaler U, Vizeli P, et al. Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects. Br J Clin Pharmacol. 2019;85(7):1474–1483. PubMed CrossRef
  28. Wittmann M, Carter O, Hasler F, et al. Effects of psilocybin on time perception and temporal control of behaviour in humans. J Psychopharmacol. 2007;21(1):50–64. PubMed CrossRef
  29. Wackermann J, Wittmann M, Hasler F, et al. Effects of varied doses of psilocybin on time interval reproduction in human subjects. Neurosci Lett. 2008;435(1):51–55. PubMed CrossRef
  30. Preller KH, Herdener M, Pokorny T, et al. The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol. 2017;27(3):451–457. PubMed CrossRef
  31. Kraehenmann R, Pokorny D, Aicher H, et al. LSD increases primary process thinking via serotonin 2A receptor activation. Front Pharmacol. 2017;8:814. PubMed CrossRef
  32. Kraehenmann R, Pokorny D, Vollenweider L, et al. Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology (Berl). 2017;234(13):2031–2046. PubMed CrossRef
  33. Preller KH, Schilbach L, Pokorny T, et al. Role of the 5-HT2A receptor in self-and other-initiated social interaction in lysergic acid diethylamide-induced states: a pharmacological fMRI study. J Neurosci. 2018;38(14):3603–3611. PubMed CrossRef
  34. Preller KH, Burt JB, Ji JL, et al. Changes in global and thalamic brain connectivity in lsd-induced altered states of consciousness are attributable to the 5-HT2A receptor. Hunt LT, Behrens TE, eds. eLife. 2018;7:e35082.
  35. Barrett FS, Preller KH, Herdener M, et al. Serotonin 2A receptor signaling underlies LSD-induced alteration of the neural response to dynamic changes in music. Cerebral Cortex. 2018;28(11):3939–3950.
  36. Preller KH, Razi A, Zeidman P, et al. Effective connectivity changes in LSD-induced altered states of consciousness in humans. Proc Natl Acad Sci U S A. 2019;116(7):2743–2748. PubMed CrossRef
  37. Pokorny T, Duerler P, Seifritz E, et al. LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making. Psychol Med. 2020;50(13):2255–2264. PubMed CrossRef
  38. Jaffe J, Dahlberg CC, Luria J, et al. Speech rhythms in patient monologues: the influence of LSD-25 and dextroamphetamine. Biol Psychiatry. 1972;4(3):243–246. PubMed
  39. Jaffe J, Dahlberg CC, Luria J, et al. Effects of LSD-25 and dextroamphetamine on speech rhythms in psychotherapy dialogues. Biol Psychiatry. 1973;6(1):93–96. PubMed
  40. Dahlberg CC, Jaffe J. The effects of LSD-25 and dextroamphetamine on the use of defensive language. J Clin Psychol. 1979;35(2):250–254. PubMed CrossRef
  41. Natale M, Dahlberg CC, Jaffe J. The effect of psychotomimetics on therapist–patient matching of speech “rhythms”. J Commun Disord. 1979;12(1):45–52. PubMed CrossRef
  42. Mueller F, Lenz C, Dolder PC, et al. Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. Transl Psychiatry. 2017;7(4):e1084. PubMed CrossRef
  43. Dolder PC, Schmid Y, Müller F, et al. LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology. 2016;41(11):2638–2646. PubMed CrossRef
  44. Liechti ME, Dolder PC, Schmid Y. Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology (Berl). 2017;234(9-10):1499–1510. PubMed CrossRef
  45. Dolder PC, Grünblatt E, Müller F, et al. A single dose of LSD does not alter gene expression of the serotonin 2a receptor gene (HTR2A) or early growth response genes (EGR1-3) in healthy subjects. Front Pharmacol. 2017;8:423. PubMed CrossRef
  46. Müller F, Lenz C, Dolder P, et al. Increased thalamic resting-state connectivity as a core driver of LSD-induced hallucinations. Acta Psychiatr Scand. 2017;136(6):648–657. PubMed CrossRef
  47. Müller F, Dolder PC, Schmidt A, et al. Altered network hub connectivity after acute LSD administration. Neuroimage Clin. 2018;18:694–701. PubMed CrossRef
  48. Schmidt A, Müller F, Lenz C, et al. Acute LSD effects on response inhibition neural networks. Psychol Med. 2018;48(9):1464–1473. PubMed CrossRef
  49. Schmid Y, Enzler F, Gasser P, et al. Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry. 2015;78(8):544–553. PubMed CrossRef
  50. Strajhar P, Schmid Y, Liakoni E, et al. Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects. J Neuroendocrinol. 2016;28(3):12374. PubMed CrossRef
  51. Schmid Y, Liechti ME. Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology (Berl). 2018;235(2):535–545. PubMed CrossRef
  52. Strassman RJ, Qualls CR. Dose-response study of N,N-dimethyltryptamine in humans, I: neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry. 1994;51(2):85–97. PubMed CrossRef
  53. Strassman RJ, Qualls CR, Uhlenhuth EH, et al. Dose-response study of N,N-dimethyltryptamine in humans, II: subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry. 1994;51(2):98–108. PubMed CrossRef
  54. Riba J, Valle M, Urbano G, et al. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther. 2003;306(1):73–83. PubMed CrossRef
  55. Riba J, Anderer P, Morte A, et al. Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers. Br J Clin Pharmacol. 2002;53(6):613–628. PubMed CrossRef
  56. Riba J, Rodríguez-Fornells A, Barbanoj MJ. Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively. Psychopharmacology (Berl). 2002;165(1):18–28. PubMed CrossRef
  57. Ludwig AM, Levine J. A controlled comparison of five brief treatment techniques employing LSD, hypnosis, and psychotherapy. Am J Psychother. 1965;19(3):417–435. PubMed CrossRef
  58. Levine J, Ludwig AM. Alterations in consciousness produced by combinations of LSD, hypnosis and psychotherapy. Psychopharmacology (Berl). 1965;7(2):123–137. PubMed CrossRef
  59. Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655–663. PubMed CrossRef
  60. Zeifman RJ, Palhano-Fontes F, Hallak J, et al. The impact of ayahuasca on suicidality: results from a randomized controlled trial. Front Pharmacol. 2019;10:1325. PubMed CrossRef
  61. Galvão ACde M, de Almeida RN, Silva EADS, et al. Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls. Front Psychiatry. 2018;9:185. PubMed CrossRef
  62. de Almeida RN, GalvãoACde M, da Silva FS, et al. Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: Observation from a randomized controlled trial. Front Psychol. 2019;10:1234. PubMed CrossRef
  63. Smigielski L, Kometer M, Scheidegger M, et al. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. Sci Rep. 2019;9(1):14914. PubMed CrossRef
  64. Smigielski L, Scheidegger M, Kometer M, et al. Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. Neuroimage. 2019;196:207–215. PubMed CrossRef
  65. Yanakieva S, Polychroni N, Family N, et al. The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2019;236(4):1159–1170. PubMed CrossRef
  66. Family N, Maillet EL, Williams LTJ, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology (Berl). 2020;237(3):841–853. PubMed CrossRef
  67. Kometer M, Schmidt A, Bachmann R, et al. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry. 2012;72(11):898–906. PubMed CrossRef
  68. Kometer M, Schmidt A, Jäncke L, et al. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci. 2013;33(25):10544–10551. PubMed CrossRef
  69. Kometer M, Pokorny T, Seifritz E, et al. Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations. Psychopharmacology (Berl). 2015;232(19):3663–3676. PubMed CrossRef
  70. Pokorny T, Preller KH, Kraehenmann R, et al. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol. 2016;26(4):756–766. PubMed CrossRef
  71. Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl). 2011;218(4):649–665. PubMed CrossRef
  72. Johnson MW, Sewell RA, Griffiths RR. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend. 2012;123(1-3):132–140. PubMed CrossRef
  73. Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, et al. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry. 2005;38(6):301–311. PubMed CrossRef
  74. Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, et al. Inhibition of return in the human 5HT2A agonist and NMDA antagonist model of psychosis. Neuropsychopharmacology. 2006;31(2):431–441. PubMed CrossRef
  75. Heekeren K, Neukirch A, Daumann J, et al. Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis. J Psychopharmacol. 2007;21(3):312–320. PubMed CrossRef
  76. Heekeren K, Daumann J, Neukirch A, et al. Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology (Berl). 2008;199(1):77–88. PubMed CrossRef
  77. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, et al. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d -methamphetamine in healthy volunteers. Psychopharmacology (Berl). 1999;142(1):41–50. PubMed CrossRef
  78. Gouzoulis-Mayfrank E, Heekeren K, Thelen B, et al. Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. Behav Pharmacol. 1998;9(7):561–566. PubMed CrossRef
  79. Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, et al. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers: a double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology. 1999;20(6):565–581. PubMed CrossRef
  80. Gouzoulis-Mayfrank E, Thelen B, Maier S, et al. Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans. Neuropsychobiology. 2002;45(4):205–212. PubMed CrossRef
  81. Kraehenmann R, Preller KH, Scheidegger M, et al. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry. 2015;78(8):572–581. PubMed CrossRef
  82. Grimm O, Kraehenmann R, Preller KH, et al. Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination. Eur Neuropsychopharmacol. 2018;28(6):691–700. PubMed CrossRef
  83. Daumann J, Heekeren K, Neukirch A, et al. Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology (Berl). 2008;200(4):573–583. PubMed CrossRef
  84. Daumann J, Wagner D, Heekeren K, et al. Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis. J Psychopharmacol. 2010;24(10):1515–1524. PubMed CrossRef
  85. Carbonaro TM, Johnson MW, Hurwitz E, et al. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. Psychopharmacology (Berl). 2018;235(2):521–534. PubMed CrossRef
  86. Barrett FS, Carbonaro TM, Hurwitz E, et al. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition. Psychopharmacology (Berl). 2018;235(10):2915–2927. PubMed CrossRef
  87. Bershad AK, Schepers ST, Bremmer MP, et al. Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers. Biol Psychiatry. 2019;86(10):792–800. PubMed CrossRef
  88. Bershad AK, Preller KH, Lee R, et al. Preliminary report on the effects of a low dose of LSD on resting-state amygdala functional connectivity. Biol Psychiatry Cogn Neurosci Neuroimaging. 2020;5(4):461–467. PubMed CrossRef
  89. Natale M, Kowitt M, Dahlberg CC, et al. Effect of psychotomimetics (LSD and dextroamphetamine) on the use of figurative language during psychoanalysis. J Consult Clin Psychol. 1978;46(6):1579–1580. PubMed CrossRef
  90. Rosenberg DE, Isbell H, Miner EJ, et al. The effect of N,N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide. Psychopharmacology (Berl). 1964;5(3):217–227. PubMed CrossRef
  91. Vollenweider FX, Vontobel P, Hell D, et al. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man–a PET study with [11C]raclopride. Neuropsychopharmacology. 1999;20(5):424–433. PubMed CrossRef
  92. Netz B, Jonsson CO, Bergqvist S. Effects of lysergic acid diethylamide (LSD-25) on normal subjects in a schizophrenia-discriminating test battery. Scand J Psychol. 1963;4(1):143–148. CrossRef
  93. Dolezal V, Hausner M. Comparative phenomenology of experimental mental alterations after application of LSD, benactyzine and phenmetrzine. Act Nerv Super (Praha). 1968;10(3):280–282. PubMed
  94. Hasler F, Grimberg U, Benz MA, et al. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl). 2004;172(2):145–156. PubMed CrossRef
  95. Carter OL, Burr DC, Pettigrew JD, et al. Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci. 2005;17(10):1497–1508. PubMed CrossRef
  96. Moreno FA, Wiegand CB, Taitano EK, et al. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):1735–1740. PubMed CrossRef
  97. Santos RG, Landeira-Fernandez J, Strassman RJ, et al. Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. J Ethnopharmacol. 2007;112(3):507–513. PubMed CrossRef
  98. Dos Santos RG, Valle M, Bouso JC, et al. Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine. J Clin Psychopharmacol. 2011;31(6):717–726. PubMed CrossRef
  99. Alonso JF, Romero S, Mañanas MÀ, et al. Serotonergic psychedelics temporarily modify information transfer in humans. Int J Neuropsychopharmacol. 2015;18(8):pyv039. PubMed CrossRef
  100. Carter OL, Pettigrew JD, Hasler F, et al. Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin. Neuropsychopharmacology. 2005;30(6):1154–1162. PubMed CrossRef
  101. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68(1):71–78. PubMed CrossRef
  102. Gasser P, Holstein D, Michel Y, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202(7):513–520. PubMed CrossRef
  103. Valle M, Maqueda AE, Rabella M, et al. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans. Eur Neuropsychopharmacol. 2016;26(7):1161–1175. PubMed CrossRef
  104. Strassman RJ, Qualls CR, Berg LM. Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans. Biol Psychiatry. 1996;39(9):784–795. PubMed CrossRef
  105. Riba J, Romero S, Grasa E, et al. Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology (Berl). 2006;186(1):93–98. PubMed CrossRef
  106. Carhart-Harris RL, Leech R, Williams TM, et al. Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. Br J Psychiatry. 2012;200(3):238–244. PubMed CrossRef
  107. Vollenweider FX, Csomor PA, Knappe B, et al. The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology. 2007;32(9):1876–1887. PubMed CrossRef
  108. Quednow BB, Kometer M, Geyer MA, et al. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology. 2012;37(3):630–640. PubMed CrossRef
  109. Kometer M, Cahn BR, Andel D, et al. The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. Biol Psychiatry. 2011;69(5):399–406. PubMed CrossRef
  110. Dos Santos RG, Grasa E, Valle M, et al. Pharmacology of ayahuasca administered in two repeated doses. Psychopharmacology (Berl). 2012;219(4):1039–1053. PubMed CrossRef
  111. Soskin RA, Grof S, Richards WA. Low doses of dipropyltryptamine in psychotherapy. Arch Gen Psychiatry. 1973;28(6):817–821. PubMed CrossRef
  112. Umbricht D, Vollenweider FX, Schmid L, et al. Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology. 2003;28(1):170–181. PubMed CrossRef
  113. Riba J, Anderer P, Jané F, et al. Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography. Neuropsychobiology. 2004;50(1):89–101. PubMed CrossRef
  114. Tagliazucchi E, Roseman L, Kaelen M, et al. Increased global functional connectivity correlates with LSD-induced ego dissolution. Curr Biol. 2016;26(8):1043–1050. PubMed CrossRef
  115. Speth J, Speth C, Kaelen M, et al. Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide. J Psychopharmacol. 2016;30(4):344–353. PubMed CrossRef
  116. Timmermann C, Spriggs MJ, Kaelen M, et al. LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm. Neuropharmacology. 2018;142:251–262. PubMed CrossRef
  117. Bravermanová A, Viktorinová M, Tylš F, et al. Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers. Psychopharmacology (Berl). 2018;235(2):491–503. PubMed CrossRef
  118. Barbanoj MJ, Riba J, Clos S, et al. Daytime ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers. Psychopharmacology (Berl). 2008;196(2):315–326. PubMed CrossRef
  119. Preller KH, Duerler P, Burt JB, et al. Psilocybin induces time-dependent changes in global functional connectivity. Biol Psychiatry. 2020;88(2):197–207. PubMed CrossRef
  120. Preller KH, Pokorny T, Hock A, et al. Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. Proc Natl Acad Sci U S A. 2016;113(18):5119–5124. PubMed CrossRef
  121. Smart RG, Storm T, Baker EF, et al. A controlled study of lysergide in the treatment of alcoholism, 1: the effects on drinking behavior. Q J Stud Alcohol. 1966;27(3):469–482. PubMed CrossRef
  122. Bernasconi F, Schmidt A, Pokorny T, et al. Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin. Cerebral Cortex. 2014;24(12):3221–3231.
  123. Zegans LS, Pollard JC, Brown D. The effects of LSD-25 on creativity and tolerance to regression. Arch Gen Psychiatry. 1967;16(6):740–749. PubMed CrossRef
  124. Wikler A, Haertzen CA, Chessick RD, et al. Reaction time (“mental set”) in control and chronic schizophrenic subjects and in postaddicts under placebo, LSD-25, morphine, pentobarbital and amphetamine. Psychopharmacology (Berl). 1965;7(6):423–443. PubMed CrossRef
  125. Pokorny T, Preller KH, Kometer M, et al. Effect of psilocybin on empathy and moral decision-making. Int J Neuropsychopharmacol. 2017;20(9):747–757. PubMed CrossRef
  126. Middlefell R. The effects of LSD on body sway suggestibility in a group of hospital patients. Br J Psychiatry. 1967;113(496):277–280. PubMed CrossRef
  127. Griffiths RR, Richards WA, McCann U, et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006;187(3):268–283, discussion 284–292. PubMed CrossRef
  128. Schmidt A, Kometer M, Bachmann R, et al. The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. Psychopharmacology (Berl). 2013;225(1):227–239. PubMed CrossRef
  129. Pasquini L, Palhano-Fontes F, Araujo DB. Subacute effects of the psychedelic ayahuasca on the salience and default mode networks. J Psychopharmacol. 2020;34(6):623–635. PubMed CrossRef
  130. Denson R, Sydiaha D. A controlled study of LSD treatment in alcoholism and neurosis. Br J Psychiatry. 1970;116(533):443–445. PubMed CrossRef
  131. Hollister LE, Shelton J, Krieger G. A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetmine in alcoholics. Am J Psychiatry. 1969;125(10):1352–1357. PubMed CrossRef
  132. Lewis CR, Preller KH, Kraehenmann R, et al. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. Neuroimage. 2017;159:70–78. PubMed CrossRef
  133. Mason NL, Kuypers KPC, Müller F, et al. Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacology. 2020;45(12):2003–2011. PubMed CrossRef
  134. Savage C, McCabe OL. Residential psychedelic (LSD) therapy for the narcotic addict: a controlled study. Arch Gen Psychiatry. 1973;28(6):808–814. PubMed CrossRef
  135. Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol. 2018;32(1):49–69. PubMed CrossRef
  136. Ditman KS, Moss T, Forgy EW, et al. Dimensions of LSD, methylphenidate and chlordiazepoxide experiences. Psychopharmacology (Berl). 1969;14(1):1–11. PubMed CrossRef
  137. Haertzen CA. Changes in correlation between responses to items of the Addiction Research Center Inventory produced by LSD-25. J Psychopharmacol. 1966;1(1):27–36.
  138. Robinson JT, Davies LS, Sack EL, et al. A controlled trial of abreaction with lysergic acid diethylamide (LSD-25). Br J Psychiatry. 1963;109(458):46–53. PubMed CrossRef
  139. Spitzer M, Thimm M, Hermle L, et al. Increased activation of indirect semantic associations under psilocybin. Biol Psychiatry. 1996;39(12):1055–1057. PubMed CrossRef
  140. Holze F, Vizeli P, Ley L, et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2021;46(3):537–544. PubMed CrossRef
  141. Holze F, Gasser P, Müller F, et al. Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled Phase II study. Biol Psychiatry. 2023;93(3):215–223. PubMed CrossRef
  142. Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022;79(10):953–962. PubMed CrossRef
  143. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603–620. PubMed CrossRef
  144. Reissig CJ, Carter LP, Johnson MW, et al. High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology (Berl). 2012;223(1):1–15. PubMed CrossRef
  145. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387(18):1637–1648. PubMed CrossRef
  146. Furukawa TA, Noma H, Caldwell DM, et al. Waiting list may be a nocebo condition in psychotherapy trials: a contribution from network meta-analysis. Acta Psychiatr Scand. 2014;130(3):181–192. PubMed CrossRef
  147. Başoğlu M, Marks I, Livanou M, et al. Double-blindness procedures, rater blindness, and ratings of outcome: observations from a controlled trial. Arch Gen Psychiatry. 1997;54(8):744–748. PubMed CrossRef
  148. Rickels K, Lipman RS, Fisher S, et al. Is a double-blind clinical trial really double-blind? a report of doctors’ medication guesses. Psychopharmacology (Berl). 1970;16(4):329–336. PubMed CrossRef
  149. Brownell KD, Stunkard AJ. The double-blind in danger: untoward consequences of informed consent. Am J Psychiatry. 1982;139(11):1487–1489. PubMed
  150. Warner J, Metcalfe C, King M. Evaluating the use of benzodiazepines following recent bereavement. Br J Psychiatry. 2001;178(1):36–41. PubMed CrossRef
  151. Himle JA, Abelson JL, Haghightgou H, et al. Effect of alcohol on social phobic anxiety. Am J Psychiatry. 1999;156(8):1237–1243. PubMed CrossRef
  152. Shlay JC, Chaloner K, Max MB, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. JAMA. 1998;280(18):1590–1595. PubMed CrossRef
  153. Fergusson D, Glass KC, Waring D, et al. Turning a blind eye: the success of blinding reported in a random sample of randomised, placebo controlled trials. BMJ. 2004;328(7437):432. PubMed CrossRef
  154. Grunebaum MF, Galfalvy HC, Choo TH, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry. 2018;175(4):327–335. PubMed CrossRef
  155. Johns RG, Barkham M, Kellett S, et al. A systematic review of therapist effects: a critical narrative update and refinement to review. Clin Psychol Rev. 2019;67:78–93. PubMed CrossRef
  156. Hayes JA, McAleavey AA, Castonguay LG, et al. Psychotherapists’ outcomes with White and racial/ethnic minority clients: first, the good news. J Couns Psychol. 2016;63(3):261–268. PubMed CrossRef
  157. Jones BDM, Razza LB, Weissman CR, et al. Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(9):e2125531. PubMed CrossRef
  158. Devilly GJ, Borkovec TD. Psychometric properties of the Credibility/Expectancy Questionnaire. J Behav Ther Exp Psychiatry. 2000;31(2):73–86. PubMed CrossRef
  159. Mathew SJ, Wilkinson ST, Altinay M, et al. ELEctroconvulsive therapy (ECT) vs ketamine in patients with treatment-resistant depression: the ELEKT-D study protocol. Contemp Clin Trials. 2019;77:19–26. PubMed CrossRef
  160. Aday JS, Heifets BD, Pratscher SD, et al. Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology (Berl). 2022;239(6):1989–2010. PubMed CrossRef
Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

Save Save

Share Share

Cite Cite

Vol 85 • 2024 • Number 3

Read the Current Issue

Editorial

Focus on Women’s Mental Health: Twenty Years and Counting

Original Research

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

Commentary

Can Our Collective Experiences As Clinicians Improve Mental Health Care?

Original Research

Prescription Opioid Use Disorder in US Adults Reporting Prescription Opioid Use

Original Research

Symptomatic Disorders Comorbid with Borderline Personality Disorder Over Time

Original Research

Aripiprazole Lauroxil Initiation Regimens
View current Issue

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe